These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8471980)

  • 1. Bisantrene in relapsed and refractory acute myelogenous leukemia.
    Spadea A; Petti MC; Aloespiriti MA; Avvisati G; De Gregoris C; Fazi P; Latagliata R; Amadori S; Mandelli F
    Leuk Lymphoma; 1993 Feb; 9(3):217-20. PubMed ID: 8471980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
    Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
    Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia.
    Canaani J; Danylesko I; Shemtov N; Zlotnick M; Lozinsky K; Benjamini O; Yerushalmi R; Nagar M; Dor C; Shimoni A; Avigdor A; Nagler A
    Eur J Haematol; 2021 Feb; 106(2):260-266. PubMed ID: 33159365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
    Leblanc T; Deméocq F; Leverger G; Baruchel A; Lemerle S; Vannier JP; Nelken B; Guillot T; Schaison G
    Med Pediatr Oncol; 1994; 22(2):119-24. PubMed ID: 8259097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
    Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA
    Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisantrene, an active drug in patients with advanced breast cancer.
    Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
    Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
    Qin TJ; Xu ZF; Wang JY; Zhou CL; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1342-6. PubMed ID: 19840480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
    Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
    Capizzi RL; Davis R; Powell B; Cuttner J; Ellison RR; Cooper MR; Dillman R; Major WB; Dupre E; McIntyre OR
    J Clin Oncol; 1988 Mar; 6(3):499-508. PubMed ID: 3162515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
    Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
    Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
    Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose carboplatin in the treatment of hematologic malignancies.
    Vogler WR
    Oncology; 1993 Nov; 50 Suppl 2():42-6. PubMed ID: 8233301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
    Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
    Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.